Deroma, a Njord Partners Portfolio Company, Appoints New CEO
27.3.2024 11:00:00 EET | Business Wire | Press release
Deroma, the world’s largest Terracotta producer, together with Njord Partners, today announce the appointment of Stefano Mele as CEO of Deroma, effective from 4 March 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327185499/en/
Stefano is a highly experienced business leader in Italy, focused on the manufacturing and industrial sectors where he has a track record of delivering successful growth strategies. Stefano’s diverse background spans various sectors, from textiles and ceramics to machines and printing. As a proven leader, he has held key roles as CEO and Managing Director in international companies and business units.
Stefano has most recently been CEO of Ceramica Dolomite, an Italian bathroom sanitaryware manufacturer specialized in ceramics with 360 employees. In less than two years, he has transformed the company, which was earmarked for closure, by relaunching the commercial production of the company, creating 7 new product series in one year and developing collaboration with other sanitaryware manufacturers to facilitate reshoring their production. Before this, Stefano was CEO of Fabbri Group, an Italian fresh food packaging designer and producer.
Stefano’s multi-lingual skills and extensive international experience spanning Europe, North and South America, India and China will be invaluable for Deroma’s global expansion.
Stefano Mele, incoming CEO, commented: “I am excited to join Deroma as CEO. I hope to use my proven leadership skills and industry expertise to drive the next phase of Deroma’s growth, working together with the whole Deroma team to produce outstanding products based on the legacy of craftmanship developed over almost 70 years. I look forward to working closely with Njord Partners to deliver on this incredible opportunity.”
Arvid Trolle, Partner at Njord Partners, said: “Stefano is a world-class leader and he will be instrumental in our exciting plans to double the size of the business and further expand globally. Stefano’s experience across the wider ceramics industry will enable Deroma to fuel the gardening passion of millions of people with the continued pursuit of the highest quality Terracotta, plastic and glazed pots.”
About Stefano Mele
Stefano began his career in 1990 as a Project Engineer at Alcatel. He went on to hold management positions at Nuova Fima, Viappiani Printong, SIAT and GEA Group. Most recently, he was CEO of Fabbri Group (2019-2022) where he achieved double-digit increases in both turnover and EBITDA through entering new markets and launching a new range of environmentally sustainable products and integrated software solutions. Since 2022, Stefano has been the CEO of Ceramica Dolomite where he has relaunched their commercial production, creating seven new product series in less than two years.
About Deroma
Deroma Group is the largest Terracotta producer globally and is headquartered in Italy. Deroma produces in Europe and the United States and operates globally, with recent expansion in the UK, Asia Pacific and Eastern Europe. As a global leader in high-end garden products, Deroma also designs and distributes pots and vases made of plastic, glazed and other materials. Deroma was successfully acquired by Njord Partners in June 2021.
To find out more visit: https://deroma.com
About Njord Partners
Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations. Its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value, with a particular focus on existing debt securities and structures.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327185499/en/
Contact information
Media enquiries:
via Camarco
njord@apcoworldwide.com
Jennifer Renwick +44 7928 471 013
Letaba Rimell +44 7715 530 664
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 12:15:00 EEST | Press release
HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612936893/en/ HUI (HUI:VSE) merges traditional and crypto finance: commences continuous trading in Vienna with leading market maker and announces impending token listing on major global exchange Emmanuelle Deba
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 10:35:00 EEST | Press release
India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of its farming population. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202606151544
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom